EXPLORING THE EFFECT OF CHRONIC INFLAMMATION ON RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN CANCER
Precision medicine has allowed for the development of monoclonal antibodies that unmask the anti-tumor immune response. These agents have provided some patients durable clinical benefit. However, PD-1 and PD-L1 inhibitor therapies are effective in a small group (10-20%) of non-small cell lung cancer...
| Main Author: | |
|---|---|
| Format: | Others |
| Published: |
UKnowledge
2018
|
| Subjects: | |
| Online Access: | https://uknowledge.uky.edu/pharmacy_etds/82 https://uknowledge.uky.edu/cgi/viewcontent.cgi?article=1086&context=pharmacy_etds |